TrialPediatric pulmonology2025

Dupilumab Plus Medium-Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High-Dose ICS in Children With Uncontrolled Moderate-to-Severe Type 2 Asthma.

Leonard B Bacharier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.